Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.

Authors	Carlo Gambacorti-Passerini, Franck Emmanuel Nicolini, Richard A Larson, Andrea Aroldi, Diletta Fontana, Rocco Piazza, Philipp le Coutre, Laura Antolini, Sarit Assouline
Journal	American journal of hematology (Am J Hematol) Vol. 97 Issue 8 Pg. E296-E298 (08 2022) ISSN: 1096-8652 [Electronic] United States
PMID	35604243 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References	Protein Kinase Inhibitors
Topics	Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy) Protein Kinase Inhibitors (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!